An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH
Starting soon · Phase 1
Conditions studied: Intracerebral Hemorrhage, Stroke-Associated Pneumonia (SAP)
In brief
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.
Key facts
- Study ID
- NCT07528235
- Run by
- Tang-Du Hospital
- People needed
- 30
- Starts
- 2026-05-01
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2026-04-14
Who can join
Age: 10 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients aged > 18 and ≤ 80 years of age;
- Can be treated with the study drug within 24 h of symptom onset;
- No fever or infection was observed upon admission;
- NIHSS score ≥10;
- Supratentorial parenchymal haematoma (≥10 mL);
- GCS score ≥ 6;
- Patients or their family members sign informed consent forms.
You may not qualify if…
- Infections within the last 4 weeks;
- Use of antibiotics within the last 2 weeks;
- Known pre-ICH dysphagia;
- Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;
- Previous disability with pre-ICH mRS score ≥ 2;
- Brainstem hemorrhage;
- Life expectancy less than 14 days;
- Death appeared imminent;
- Pregnancy or within 30 d of delivery;
- Previous use (within 1 month) of β-blockers or reserpine;
- Bronchial asthma or COPD;
- Cardiogenic shock;
- Degree II-III atrioventricular blocks;
- Severe or acute heart failure;
- Heart rate < 65 beats/min;
- Known to be allergic to propranolol;
- Severe liver or renal insufficiency;
- History of malignant tumors;
- Currently participating in other interventional clinical trials;
- Currently, immunosuppressants and immunotherapies are being administered.
Where it is running
- Department of Neurosurgery , Tangdu Hospital, Fourth Military Medical University — Xi'an, Shaanxi, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.